ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2609

Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice

Dalifer Freites Núñez1, Zulema Rosales Rosado1,2, Judit Font Urgelles2, Isabel Hernández-Rodríguez2, Leticia Leon1, Gloria Candelas Rodriguez2, Luis Rodriguez-Rodriguez1, Benjamín Fernández-Gutiérrez1,2, Juan A Jover Jover2 and Lydia A Alcazar1, 1Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 2Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Clinical practice, DMARDs, psoriatic arthritis and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that benefits from DMARDs, in this regard knowing more about these therapies is a great step forward in the management of these patients in daily clinical practice. Objetives: To evaluate the survival of DMARDs used in recent diagnose PsA patients as well as the causes of discontinuation and to analyze the possible associated factors. Methods: Retrospective longitudinal observational study. Subjects: Inception cohort of patients from January 2010 to December 2014, and followed up to December 2016, diagnosed with PsA according to ICD-10 code. Main outcome: discontinuation of conventional DMARDs (cDMARDs) and biological DMARDs (bDMARDs) due to: Adverse drug reactions (ADRs); Improvement or remission; Inefficacy; Patient`s decision and Physician’s decision. Covariables: sociodemographic and clinical. Statistical analysis: To estimate DMARDs discontinuation rates, survival techniques were used, expressing the incidence rate (IR) per 100 patients*year with their respective CI at 95%. Multivarite Cox regression models were performed to analyze the factors associated with DMARDs discontinuation and the results were expressed in Hazard ratio(HR) and 95%CI. Results: 191 patients with recent diagnosis of PsA were included, with a 379.7 Patients*year follow-up. 50.3% were male, the mean age at diagnosis was 50±14.6 years old. 46.6% of the patients had a history of cutaneous psoriasis. HLA-B27 was positive in 20% of patients. 50% of the patients started a DMARDs at the first visit. Throughout the follow-up, all patients received cDMARDs and 23 used bDMARDs. The median DMARD per patient was 2[1-3]. Methotrexate (MTX) was the most used drug 69.7%. According to the treatment regimen, 30% were on combination therapy, the most frequent was antiTNF+MTX (33%). 103 discontinuations were recorded with a IR 27.1[22.3-32.9] within these, 44 were related with ADRs (IR 11.5[8.6-15.5]), 24 (IR 6.3[3.5-11.1]) were due to inefficiency, 9 (IR 2.3[1.2-4.5]) were registered after remission, 12 (IR 3.1[1.7-5.5]) by decision of the patient and 12 (IR 3.1[1.7-5.5]) by doctor’s decision. The DMARDs median survival was 1.8 years [1.4-2.7]. Table 1 shows the discontinuation rates for each type of DMARDs and the multivariate analysis for the factors associeted with DMARDs discontinuation is in Table 2. Conclusion: In our study, the DMARD discontinuation rate was 27.1, mainly related with ADRs. We have also found some clinical and therapy regimen factors that can modify the DMARDs survival on PsA. We observed that MTX, presented the longest survival independent of the rest of the factors.

Table 1. Patients*years Events(n) IR 95%CI
MTX orally 243.46 53 21.77 16.63-28.49
Sc MTX 49.90 18 36.07 22.73-57.25
Salazopyrine 84.80 30 35.37 24.73-50.59
Leflunomide 21.83 10 45.80 24.64-85.13
Antimalarials 25.34 8 31.56 15.78-63.12
bDMARDs 57.56 25 43.43 29.35-64.28
Table 2. HR 95% CI
Women 1.51 0.61-3.09
Age at diagnosis 0.97 0.97-1.01
Distress level 1.87 1.00-3.48
CRP ≥ 1.05gr/dL 1.85 0.99-3.48
Combination therapy 2.36 1.46-3.80
bDMARDs 1.05 0.52-2.11
MTX vs rest DMARDs 0.53 0.31-0.91

Disclosure: D. Freites Núñez, None; Z. Rosales Rosado, None; J. Font Urgelles, None; I. Hernández-Rodríguez, None; L. Leon, None; G. Candelas Rodriguez, None; L. Rodriguez-Rodriguez, None; B. Fernández-Gutiérrez, None; J. A. Jover Jover, None; L. A. Alcazar, None.

To cite this abstract in AMA style:

Freites Núñez D, Rosales Rosado Z, Font Urgelles J, Hernández-Rodríguez I, Leon L, Candelas Rodriguez G, Rodriguez-Rodriguez L, Fernández-Gutiérrez B, Jover Jover JA, Alcazar LA. Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/survival-of-disease-modifying-drugs-in-patients-with-recent-diagnosis-of-psoriatic-arthritis-in-daily-clinical-practice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survival-of-disease-modifying-drugs-in-patients-with-recent-diagnosis-of-psoriatic-arthritis-in-daily-clinical-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology